Cleared Special

K251634 - LZI Fentanyl III Enzyme Immunoassay (FDA 510(k) Clearance)

Jun 2025
Decision
20d
Days
Class 2
Risk

K251634 is an FDA 510(k) clearance for the LZI Fentanyl III Enzyme Immunoassay. This device is classified as a Enzyme Immunoassay, Opiates (Class II - Special Controls, product code DJG).

Submitted by Lin-Zhi International, Inc. (Santa Clara, US). The FDA issued a Cleared decision on June 18, 2025, 20 days after receiving the submission on May 29, 2025.

This device falls under the Toxicology FDA review panel. Regulated under 21 CFR 862.3650.

Submission Details

510(k) Number K251634 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 29, 2025
Decision Date June 18, 2025
Days to Decision 20 days
Submission Type Special
Review Panel Toxicology (TX)
Summary Summary PDF

Device Classification

Product Code DJG — Enzyme Immunoassay, Opiates
Device Class Class II - Special Controls
CFR Regulation 21 CFR 862.3650

Similar Devices — DJG Enzyme Immunoassay, Opiates

All 23
Labcorp Fentanyl Urine Visual Test
K252684 · Medtox Diagnostics, Inc. · Jan 2026
LZI Buprenorphine II Enzyme Immunoassay
K253082 · Lin-Zhi International, Inc. · Jan 2026
SEFRIA™ Hydrocodone Oral Fluid
K252520 · Immunalysis Corporation · Sep 2025
Healgen® AccuFluor Fentanyl Fluorescence Immunoassay (FIA)Test Kit - Qualitative
K251972 · Healgen Scientific, LLC · Aug 2025
CEDIA Heroin Metabolite (6-AM) Assay
K231007 · Microgenics Corporation · Sep 2023
Emit® II Plus Buprenorphine Assay
K221605 · Siemens Healthcare Diagnostics, Inc. · Jul 2023